VIB and AB Biotek join forces to develop superior yeast strains for bioethanol production

Collaboration to meet global needs of bioethanol industry

AB Biotek, a division of Associated British Foods, has partnered with VIB, Flanders’ leading life sciences research institute, on research collaboration and the development of core inputs within the global bioethanol industry. ​ 

The primary research focused on the development of new yeast options, including strain screening for relevant traits, improvement through breeding, evaluation and selection of subsequent hybrids and testing, and ultimately commercialization of selected strains. 

This collaboration has taken place over many years, and to officially formalize our relationship with VIB’s excellent group of fermentation scientists is a significant measure. Our collective goal is to provide new, market-leading bioethanol yeast solutions, and having the opportunity to patent new technology with our partners is immensely rewarding. - John H. Evans, PhD, vice president of innovation – yeast, AB Biotek

Recent work under the Summit commercial brand name – conducted at both VIB’s facilities at KU Leuven, Belgium and the Fleischmann’s Technology Center within AB Biotek North America’s headquarters in St. Louis, Missouri – has focused on the selection of yeast strains within a collection of more than 500 under consideration across a wide range of previous end-use segments.

Our work with AB Biotek was very rewarding because it enabled us to exploit our joint expertise in fermentation technology and advanced yeast breeding to generate natural yeast variants that increase bioethanol yields, and as such helps us take a new step toward a more efficient production of sustainable bio-based fuels. - Kevin Verstrepen, PhD, head of the VIB-KU Leuven Center for Microbiology
Driving innovation in close collaboration with industry is an important mission of VIB. - Frederik Van Leemputte, PhD, Business Development Manager at VIB.

Joran Lauwers

Joran Lauwers

Press Contact, VIB

About AB Biotek

AB Biotek contributes to the success of customers through the delivery of customized fermentation-based, sustainable solutions containing proprietary and/or purposefully sourced microorganisms to create differentiated food, beverage, health & nutrition business opportunities. ​ Science and advanced microorganism fermentation technology are core enablers. ​ AB Biotek has commercial scale production and research development facilities located around the world. ​ For more information about our product applications and unmatched technical service capabilities, please visit www.abbiotek.com or www.pinnaclebrewingingredients.com.

About the VIB-KU Leuven Center for Microbiology

The big impact of bacteria on our health, the use of yeasts to enhance the production of chocolate, beer or bioethanol, yeast as a model system for studying human disease ... these are just a few of the research areas for the scientists at the VIB-KU Leuven Center for Microbiology. Their research also has important implications in various fields of application.

About KU Leuven

KU Leuven is Europe’s most innovative university (Reuters) and ranks 45th in the Times Higher Education World University Rankings. As Belgium's largest university, KU Leuven welcomes 60,000 students from over 140 countries. Its 7,000 researchers are active in a comprehensive range of disciplines. KU Leuven is a founding member of the League of European Research Universities (LERU) and has a strong European and international orientation. University Hospitals Leuven, its network of research hospitals, provides high-quality healthcare and develops new therapeutic and diagnostic insights with an emphasis on translational research.

Share

Latest stories

Website preview
Platform Enhances Purity and Reproducibility of Extracellular Vesicle Proteomics
Low-cost, high-throughput method improves purity and reproducibility of EV-based proteomics
press.vib.be
Website preview
Animab Secures EUR 10 Million in Series B Financing to Launch Nanoprotec® in Europe and Expand Pipeline
Zwijnaarde, 1 July 2025 – Animab (“the Company”), a leader in pioneering first-in-class oral antibody solutions for unmet needs in production animals, announces the successful closing of a EUR 10 million Series B funding round. The investment will support the commercial launch of Animab Nanoprotec® as well as the advancement of its broader pipeline. This financing round follows shortly after Animab’s exclusive distribution agreement with Huvepharma1, reinforcing the strong momentum behind the upcoming commercialization of Nanoprotec® in the European market.
press.vib.be
Website preview
Researchers uncover surprising role of 'natural killer' cells in resistance to cancer immunotherapy
Targeting NK cells could open the door to more effective immunotherapy in resistant tumors
press.vib.be

About VIB

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be